E
15.54
0.25 (1.64%)
| Previous Close | 15.29 |
| Open | 15.52 |
| Volume | 401,255 |
| Avg. Volume (3M) | 354,532 |
| Market Cap | 896,685,952 |
| Price / Earnings (TTM) | 12.95 |
| Price / Sales | 1.04 |
| 52 Weeks Range | |
| Earnings Date | 19 Nov 2024 - 25 Nov 2024 |
| TTM Dividend Yield | 2.90% |
| Profit Margin | 6.23% |
| Operating Margin (TTM) | 29.98% |
| Diluted EPS (TTM) | 1.34 |
| Quarterly Revenue Growth (YOY) | -4.80% |
| Quarterly Earnings Growth (YOY) | -3.30% |
| Current Ratio (MRQ) | 2.11 |
| Operating Cash Flow (TTM) | 38.70 M |
| Levered Free Cash Flow (TTM) | 46.59 M |
| Return on Assets (TTM) | 9.64% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Instruments & Supplies (US) | Mixed | Mixed |
| Medical Instruments & Supplies (Global) | Mixed | Mixed | |
| Stock | Embecta Corp. | Bullish | Bullish |
AIStockmoo Score
0.8
| Analyst Consensus | 3.5 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 4.0 |
| Average | 0.75 |
|
Embecta Corp is a medical technology company. The company develops innovative technology, services, and solutions that help advance both clinical therapy for patients and clinical processes for healthcare providers. Its products include BD Pyxis, PureWick, Phasix among others. |
|
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Investment Style | Small Value |
| % Held by Insiders | 0.47% |
| % Held by Institutions | 98.23% |
| 52 Weeks Range | ||
| Median | 26.00 (67.31%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| BTIG | 27 Nov 2024 | 26.00 (67.31%) | Buy | 20.59 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 19 Dec 2024 | Announcement | embecta to Participate at the 43rd Annual J.P. Morgan Healthcare Conference |
| 26 Nov 2024 | Announcement | Embecta Corp. Reports Fiscal 2024 Fourth Quarter and Full Year Financial Results; Provides Initial Fiscal Year 2025 Financial Guidance; Discontinues Insulin Patch Pump Program; and Announces Restructuring to Streamline Operations and Reduce Costs |
| 26 Nov 2024 | Announcement | embecta Announces Quarterly Cash Dividend |
| 12 Nov 2024 | Announcement | embecta to Report Fiscal Fourth Quarter and Full Year 2024 Financial Results |
| 07 Nov 2024 | Announcement | embecta Celebrates National Diabetes Awareness Month by Ringing Nasdaq Closing Bell |
| TTM Dividend Yield | 2.90% |
| 2Y Average Dividend Yield | 2.28% |
| Payout Ratio | 50.00% |
| Expected Next Dividend Payment | Mar 2025 |
| Ex Date | Announcement Date | Payment Date | Details |
|---|---|---|---|
| 27 Aug 2024 | 09 Aug 2024 | 13 Sep 2024 | 0.15 Cash |
| 24 May 2024 | 09 May 2024 | 14 Jun 2024 | 0.15 Cash |
| 27 Feb 2024 | 09 Feb 2024 | 15 Mar 2024 | 0.15 Cash |
| 01 Dec 2023 | 21 Nov 2023 | 15 Dec 2023 | 0.15 Cash |
| 24 Aug 2023 | 08 Aug 2023 | 13 Sep 2023 | 0.15 Cash |
| 25 May 2023 | 12 May 2023 | 13 Jun 2023 | 0.15 Cash |
| 24 Feb 2023 | 14 Feb 2023 | 13 Mar 2023 | 0.15 Cash |
| 29 Dec 2022 | 20 Dec 2022 | 11 Jan 2023 | 0.15 Cash |
| 25 Aug 2022 | 12 Aug 2022 | 14 Sep 2022 | 0.15 Cash |
Annual Dividend Yield
| Year | Annual Dividend ($) | Frequency/Year | Yield % |
|---|---|---|---|
| 2024 | 0.450 | 3 | 2.90 |
| 2023 | 0.750 | 5 | 3.96 |
| 2022 | 0.150 | 1 | 0.59 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |